Understanding the function and significance of microRNAs (miRNAs or miRs) in the regulation of xenobiotic disposition and actions is important for developing new rational therapies. However, there is a lack of efficient means to produce large quantities of natural, biologically active miRNA agents for prospective mechanistic and therapeutic studies in vivo. To fill this gap, the PI's lab has investigated the feasibility of producing recombinant pre-miRNA (mir) agents, which may be processed to functional mature miRNAs in human cells. These studies have led the PI to develop a novel pre-miRNA-based optimal noncoding RNA scaffold (OnRS) for achieving a consistent, high-yield, and large-scale expression of recombinant OnRS/miRNAs and OnRS/siRNAs in a common strain of E. coli. After purification and structural characterization, recombinant ncRNAs were found to be selectively processed to target miRNAs (or siRNAs) within various human cell line systems. Consequently, recombinant miRNAs reduced target gene expression, altered cellular xenobiotic metabolism capacity, and sensitized the cells to small-molecule drugs. Moreover, in vivo-jetPEI-formulated recombinant ncRNAs were well tolerated in mouse models and suppressed target gene expression in vivo. Given these exciting preliminary findings, we hypothesize that biologically active miRNA agents (e.g., miR-27b, miR-34a, and miR-124) can be engineered on a large scale using this novel OnRS-based recombinant RNA technique, and the OnRS/miRNAs may serve as unique tools to define the importance of miRNAs in the modulation of drug disposition and efficacy. To test this hypothesis, we will refine and standardize OnRS technique, produce a set of OnRS/miRNA and OnRS/siRNA agents, and define their primary structural characteristics including posttranscriptional modifications (Aim 1), delineate the mechanistic functions of OnRS/miRNAs in the control of cellular xenobiotic metabolism and disposition in vitro (Aim 2), and establish the efficacy of OnRS/miRNAs in the modulation of pharmacokinetics and therapeutic outcomes in clinically relevant animal models in vivo (Aim 3). This research shall establish a novel OnRS-based recombinant RNA technique and open new avenues to miRNA pharmacoepigenetics.
The proposed research is to establish a novel technique for achieving high-yield, large-scale production of recombinant noncoding RNAs, and to employ these new agents to define their mechanistic functions in the control of xenobiotic disposition and drug efficacy. Results are anticipated to provide insights into interindividual variations in drug disposition and development of improved therapies.
|Yu, Ai-Ming; Jian, Chao; Yu, Allan H et al. (2018) RNA therapy: Are we using the right molecules? Pharmacol Ther :|
|Zhang, Qian-Yu; Ho, Pui Yan; Tu, Mei-Juan et al. (2018) Lipidation of polyethylenimine-based polyplex increases serum stability of bioengineered RNAi agents and offers more consistent tumoral gene knockdown in vivo. Int J Pharm 547:537-544|
|Alegre, Fernando; Ormonde, Amanda R; Snider, Kellie M et al. (2018) A genetically engineered microRNA-34a prodrug demonstrates anti-tumor activity in a canine model of osteosarcoma. PLoS One 13:e0209941|
|Ho, Pui Yan; Duan, Zhijian; Batra, Neelu et al. (2018) Bioengineered Noncoding RNAs Selectively Change Cellular miRNome Profiles for Cancer Therapy. J Pharmacol Exp Ther 365:494-506|
|Li, Peng-Cheng; Tu, Mei-Juan; Ho, Pui Yan et al. (2018) Bioengineered NRF2-siRNA Is Effective to Interfere with NRF2 Pathways and Improve Chemosensitivity of Human Cancer Cells. Drug Metab Dispos 46:2-10|
|Jian, Chao; Tu, Mei-Juan; Ho, Pui Yan et al. (2017) Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models. Oncotarget 8:30742-30755|
|Yu, Ai-Ming; Ingelman-Sundberg, Magnus; Cherrington, Nathan J et al. (2017) Regulation of drug metabolism and toxicity by multiple factors of genetics, epigenetics, lncRNAs, gut microbiota, and diseases: a meeting report of the 21st International Symposium on Microsomes and Drug Oxidations (MDO). Acta Pharm Sin B 7:241-248|
|Jilek, Joseph L; Tian, Ye; Yu, Ai-Ming (2017) Effects of MicroRNA-34a on the Pharmacokinetics of Cytochrome P450 Probe Drugs in Mice. Drug Metab Dispos 45:512-522|
|Duan, Zhijian; Yu, Ai-Ming (2016) Bioengineered non-coding RNA agent (BERA) in action. Bioengineered 7:411-417|
|Zhao, Yong; Tu, Mei-Juan; Wang, Wei-Peng et al. (2016) Genetically engineered pre-microRNA-34a prodrug suppresses orthotopic osteosarcoma xenograft tumor growth via the induction of apoptosis and cell cycle arrest. Sci Rep 6:26611|